IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

NCT06014528 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer Recurrent

Interventions

DRUG: IN10018
DRUG: Placebo of IN10018
DRUG: Pegylated Liposomal Doxorubicin

Sponsor

InxMed (Shanghai) Co., Ltd.